title: Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations?
authors.forename: Amer A
authors.initials: AA
authors.lastname: Alkhatib
authors.forename: Fateh A
authors.initials: FA
authors.lastname: Elkhatib
authors.forename: Omar F
authors.initials: OF
authors.lastname: Khatib
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000077144:Clopidogrel; D004347:Drug Interactions; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D017751:Safety Management; D013923:Thromboembolism / Q000517:prevention & control; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000925:Anticoagulants; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D009853:Omeprazole; D013988:Ticlopidine